Ovid Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 9, 2022, details the results of Ovid Therapeutics Inc.'s Annual Meeting of Stockholders. The company is an emerging growth company incorporated in Delaware with its principal executive offices in New York, New York. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "OVID".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.
Material Changes and Voting Results
As of April 11, 2022, there were 70,417,345 shares of common stock outstanding. A quorum was established with 41,220,715 shares (58.53%) present in person or by proxy. The following proposals were voted upon:
- Proposal 1: Election of Directors
- Kevin Fitzgerald: Elected with 23,339,939 votes For, 76,303 Withheld, and 17,804,473 Broker Non-Votes.
- Bart Friedman: Elected with 17,204,205 votes For, 6,212,037 Withheld, and 17,804,473 Broker Non-Votes.
- Both nominees were elected to serve a three-year term until the 2025 Annual Meeting.
- Proposal 2: Ratification of Independent Auditors
- Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes: 40,049,679 For, 1,157,936 Against, 13,100 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the Company's definitive proxy statement filed on April 29, 2022.
Key Facts for Investor Verification
- Verify the full text of the definitive proxy statement filed on April 29, 2022, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Confirm the total number of shares outstanding and the specific breakdown of broker non-votes, which were significant in the director election (17,804,473 shares).
- Review the company's most recent 10-K or 10-Q filings for financial metrics, as this 8-K contains no financial data.